FORMULATION OF COMBINATION OF THREE ANTIVIRAL COMPOUNDS
AU2016200676A1
N-[(2'R)-2 '-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl] -L-alanine 1-methylethyl ester and process for its production
AU2015252113A1
Compounds
AU2015252077A1
Antiviral compounds
AU2015243078A1
Antiviral compounds
TW202014413A
Processes for preparing antiviral compounds
TW201609745A
Solid forms of an antiviral compound
AU2014274548A1
N- [ (2 ' R) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -L-alanine 1-methylethyl ester and process for its production
TW201609785A
Solid forms of an antiviral compound
WO2015084741A2
Methods of treating hepatitis c virus infection in subjects with cirrhosis
AU2014215983A1
Nucleoside phosphoramidate prodrugs
AU2014203349A1
Antiviral compounds
US2014357595A1
Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
WO2014137929A1
Methods for treating hepatitis c virus
US2014343008A1
Hepatitis c treatment
AP201508630A0
Combination formulation of two antiviral compounds
AU2014202687A1
Combination formulation of two antiviral compounds
WO2015030854A1
Solid dispersion formulation of an antiviral compound
CN105517540A
Combination formulation of two antiviral compounds
